Literature DB >> 15265810

Effects of phosphodiesterase inhibitors on interleukin-4 and interleukin-13 generation from human basophils.

Nahid Eskandari1, Thulani Wickramasinghe, Peter T Peachell.   

Abstract

The aim of the present study was to determine whether inhibition of cyclic nucleotide phosphodiesterase (PDE) modulates the stimulated generation of the cytokines, interleukin-4 (IL-4) and IL-13, from human basophils. This was addressed by evaluating the effects of both nonselective and selective inhibitors of PDEs on the generation of cytokines from basophils. The nonselective PDE inhibitors, isobutyl-methylxanthine (IBMX) and theophylline, attenuated the IgE-mediated generation of IL-4 and IL-13 and, also, the release of histamine from basophils. The effects of the isoform-selective inhibitors, 8-methoxymethyl-IBMX (PDE 1 inhibitor), siguazodan (PDE3 inhibitor), rolipram (PDE4 inhibitor), denbufylline (PDE4 inhibitor), Org 30029 (mixed PDE3 and 4 inhibitor) and zaprinast (PDE5 inhibitor), were studied. Of these selective compounds, only rolipram, denbufylline and Org 30029 inhibited the IgE-dependent generation of IL-4, IL-13 and histamine from basophils to a statistically significant (P<0.05) degree. The effects of isoform-selective inhibitors on basophils activated by IL-3 were evaluated. The IL-3-induced generation of IL-4, IL-13 and histamine was inhibited to a statistically significant (P<0.05) extent, only by compounds that act as inhibitors of PDE4. These data suggest that inhibition of PDE4 can regulate the generation of cytokines from human basophils.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265810      PMCID: PMC1575198          DOI: 10.1038/sj.bjp.0705892

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

Review 1.  Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.

Authors:  J E Souness; D Aldous; C Sargent
Journal:  Immunopharmacology       Date:  2000-05

Review 2.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

Authors:  S H Soderling; J A Beavo
Journal:  Curr Opin Cell Biol       Date:  2000-04       Impact factor: 8.382

Review 3.  Modulation of inflammation and immunity by cyclic AMP.

Authors:  H R Bourne; L M Lichtenstein; K L Melmon; C S Henney; Y Weinstein; G M Shearer
Journal:  Science       Date:  1974-04-05       Impact factor: 47.728

4.  Pharmacologic control of allergic histamine release in vitro: evidence for an inhibitory role of 3',5'-adenosine monophosphate in human leukocytes.

Authors:  H R Bourne; L M Lichtenstein; K L Melmon
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

5.  An automated continuous-flow system for the extraction and fluorometric analysis of histamine.

Authors:  R P Siraganian
Journal:  Anal Biochem       Date:  1974-02       Impact factor: 3.365

6.  Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine.

Authors:  J T Schroeder; R P Schleimer; L M Lichtenstein; W Kreutner
Journal:  Clin Exp Allergy       Date:  2001-09       Impact factor: 5.018

7.  Evidence that the anti-spasmogenic effect of the beta-adrenoceptor agonist, isoprenaline, on guinea-pig trachealis is not mediated by cyclic AMP-dependent protein kinase.

Authors:  L Spicuzza; M G Belvisi; M A Birrell; P J Barnes; D J Hele; M A Giembycz
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

8.  Histamine release in vitro: inhibition by catecholamines and methylxanthines.

Authors:  L M Lichtenstein; S Margolis
Journal:  Science       Date:  1968-08-30       Impact factor: 47.728

Review 9.  Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling.

Authors:  Marco Conti; Wito Richter; Celine Mehats; Gabriel Livera; Jy-Young Park; Catherine Jin
Journal:  J Biol Chem       Date:  2002-12-18       Impact factor: 5.157

10.  Basophil counting with a new staining method using alcian blue.

Authors:  H S Gilbert; L Ornstein
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

View more
  3 in total

1.  Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro.

Authors:  J Milara; M Armengot; P Bañuls; H Tenor; Rolf Beume; E Artigues; J Cortijo
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 2.  Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases.

Authors:  Theerasuk Kawamatawong
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 3.  A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool.

Authors:  Nahid Eskandari; Omid Mirmosayyeb; Gazaleh Bordbari; Reza Bastan; Zahra Yousefi; Alireza Andalib
Journal:  J Res Pharm Pract       Date:  2015 Oct-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.